Contrasting Tvardi Therapeutics (NASDAQ:TVRD) and Nicox (OTCMKTS:NICXF)

Tvardi Therapeutics (NASDAQ:TVRD) and Nicox (OTCMKTS:NICXF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

Profitability

This table compares Tvardi Therapeutics and Nicox’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Nicox	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tvardi Therapeutics and Nicox, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1	3	3	1	2.50
Nicox	0	1	1	0	2.50

Tvardi Therapeutics presently has a consensus target price of $39.80, indicating a potential upside of 1,413.31%. Given Tvardi Therapeutics’ higher possible upside, equities research analysts plainly believe Tvardi Therapeutics is more favorable than Nicox.

Risk & Volatility

Tvardi Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Nicox has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500.

Institutional & Insider Ownership

44.7% of Tvardi Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Tvardi Therapeutics and Nicox”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14 million	3.46	-$18.21 million	($3.10)	-0.85
Nicox	$3.59 million	5.76	-$24.23 million	N/A	N/A

Tvardi Therapeutics has higher revenue and earnings than Nicox.

Summary

Tvardi Therapeutics beats Nicox on 8 of the 11 factors compared between the two stocks.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

About Nicox

Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.